300841 Stock Overview
Chengdu Kanghua Biological Products Co., Ltd. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 4/6 |
Rewards
Risk Analysis
Chengdu Kanghua Biological Products Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥57.50 |
| 52 Week High | CN¥84.05 |
| 52 Week Low | CN¥44.01 |
| Beta | 2.46 |
| 11 Month Change | -8.90% |
| 3 Month Change | 16.92% |
| 1 Year Change | -28.53% |
| 33 Year Change | -47.88% |
| 5 Year Change | n/a |
| Change since IPO | -81.21% |
Recent News & Updates
Recent updates
Shareholder Returns
| 300841 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | -12.7% | -6.3% | -4.1% |
| 1Y | -28.5% | -18.6% | 3.8% |
Return vs Industry: 300841 underperformed the CN Biotechs industry which returned -19.7% over the past year.
Return vs Market: 300841 underperformed the CN Market which returned 1.9% over the past year.
Price Volatility
| 300841 volatility | |
|---|---|
| 300841 Average Weekly Movement | 10.8% |
| Biotechs Industry Average Movement | 8.8% |
| Market Average Movement | 8.2% |
| 10% most volatile stocks in CN Market | 12.6% |
| 10% least volatile stocks in CN Market | 5.6% |
Stable Share Price: 300841's share price has been volatile over the past 3 months compared to the CN market.
Volatility Over Time: 300841's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of CN stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 700 | Hongbo Wu | www.kangh.com |
Chengdu Kanghua Biological Products Co., Ltd. engages in the research, development, production, sale, and technical service of biological products in China. It offers group ACYW135 meningococcal polysaccharide vaccines; and freeze-dried human diploid cell rabies vaccines.
Chengdu Kanghua Biological Products Co., Ltd. Fundamentals Summary
| 300841 fundamental statistics | |
|---|---|
| Market cap | CN¥7.47b |
| Earnings (TTM) | CN¥546.18m |
| Revenue (TTM) | CN¥1.65b |
13.7x
P/E Ratio4.5x
P/S RatioIs 300841 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 300841 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.65b |
| Cost of Revenue | CN¥100.77m |
| Gross Profit | CN¥1.55b |
| Other Expenses | CN¥1.00b |
| Earnings | CN¥546.18m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 4.20 |
| Gross Margin | 93.88% |
| Net Profit Margin | 33.15% |
| Debt/Equity Ratio | 6.3% |
How did 300841 perform over the long term?
See historical performance and comparison